NasdaqGS:STBA
NasdaqGS:STBABanks

A Look At S&T Bancorp (STBA) Valuation After Higher Dividend And New Share Repurchase Program

S&T Bancorp (STBA) just paired a higher quarterly dividend with a fresh share repurchase authorization, giving investors new information on how the bank is currently using its capital and rewarding shareholders. See our latest analysis for S&T Bancorp. Those dividend and buyback moves come after a stretch where the share price has been relatively firm, with a 90 day share price return of 13.57% and a 1 year total shareholder return of 13.58%. This suggests momentum has been building rather...
NasdaqGS:CASH
NasdaqGS:CASHBanks

Pathward Financial (CASH) Is Up 11.0% After EPS Beat And Buyback Completion - What's Changed

Pathward Financial, Inc. reported first-quarter 2026 results for the period ended December 31, 2025, with net interest income of US$119.34 million versus US$125.25 million a year earlier, while net income rose to US$35.17 million and diluted earnings per share from continuing operations increased to US$1.57 from US$1.23. Alongside these earnings, the company completed a share repurchase program launched in August 2023, buying back 2,713,988 shares for US$203.89 million, which, together with...
NasdaqGS:WGS
NasdaqGS:WGSHealthcare

Surging AI-Driven Genetic Testing Demand Might Change The Case For Investing In GeneDx Holdings (WGS)

GeneDx Holdings recently reported very strong revenue growth of 51.90%, highlighting accelerating demand for its AI-powered genetic testing services focused on pediatric and rare disease diagnostics. This expansion showcases how GeneDx’s use of AI in next-generation sequencing and clinical reporting is helping it build a differentiated position in genomics-focused healthcare. Next, we’ll examine how this AI-driven genetic testing momentum shapes GeneDx Holdings’ investment narrative in light...
NasdaqGS:TEM
NasdaqGS:TEMLife Sciences

Should Tempus AI’s (TEM) New Immunotherapy Prediction Data Shift How Investors View Its Moat?

In January 2026, Tempus AI reported study results showing its Immune Profile Score (IPS) algorithm more accurately predicts outcomes for cancer patients receiving immune checkpoint inhibitors than conventional biomarkers such as tumor mutational burden, microsatellite instability, and PD-L1. The findings suggest IPS could broaden access to immunotherapy by identifying treatment-responsive patients with microsatellite stable colorectal cancer and rare metastatic tumors who might be missed by...
NYSE:MTZ
NYSE:MTZConstruction

A Look At MasTec (MTZ) Valuation After Zacks Rank Upgrade And Infrastructure Optimism

Why MasTec’s latest analyst upgrade matters MasTec (MTZ) has just been upgraded to a Zacks Rank #2 based on improving earnings estimates, a shift that comes alongside continued analyst support related to the company’s infrastructure and renewable energy exposure. See our latest analysis for MasTec. MasTec’s share price has eased 1.5% over the past day but still sits at US$244.75 after a strong run, with a 30-day share price return of 9.9% and a 1-year total shareholder return of 75.4%. This...